The proposed Center for Transport OncoPhysics (CTO) is a collaborative program among five institutions. The Principal Investigator is Dr. Mauro Ferrari (UTHSC-H) and the Senior Co-Investigator is Dr. Steven Curley (MDACC). Thus, the first overall specific aim of the proposed CTO is to construct a ?reference system? for the understanding of cancer, where the multi-dimensional ?unit vectors? are the differential laws of transport physics across a fundamental set of biobarriers as they present themselves and evolve in tumorigenesis (i.e., ?transport oncophysics?). The second overarching Specific Aim is to demonstrate the therapeutic efficacy of the novel systems and approaches developed within the CTO (multi-stage systems, nanoshuttles, carbon nanotubes, gold colloids, oral administration carriers) in the respective animal models. The proposed CTO will feature: 1. A single scientific framework (?transport oncophysics? as the differential, and biological barriers as the transport nodes);2. An integrated ?multiple multi-scale? approach (our mathematics, engineered probes, and imaging instrumentation are all multiscale, and are here employed to study the multiscale architecture of the biological barriers) reflected in shared cores and all project platforms being available to serve as cores for other projects;3. A ?dual-intent? operational approach, with the engineered transport probes used for basic discovery also being employed for the demonstration of innovative therapeutic modalities addressing unsolved clinical needs in two cancer focus cluster areas;4. An integrated choice of cancer focus and animal models. The first focus cluster is liver cancer, both primary and metastatic (Projects 1-2), the second is colorectal cancer (Projects 3), with cogent connections being the liver metastasis aspect of colorectal cancer, and the choice of unified animal models that sincerely recapitulate human diseases, under the guidance of Dr. Fidler. Further investigations that address complementary and synergistic aspects of transport onco-physics will be launched throughout the operations of the CTO by means of the Pilot Projects mechanism.

Public Health Relevance

The proposed Center for Transport Oncophysics (CTO) desires to understand the physics of mass transport within a cancer lesion and mass exchanges between cancer and surrounding host biology. Once such mechanisms are understood, the CTO hopes to develop and improve cancer diagnosis and treatment. With improved cancer diagnosis and treatment, the burden of cancer will be lessened and the eradication of cancer possible.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-9 (O1))
Program Officer
Eljanne, Mariam
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Methodist Hospital Research Institute
United States
Zip Code
Koay, Eugene J; Lee, Yeonju; Cristini, Vittorio et al. (2018) A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 24:5883-5894
Mu, Chaofeng; Wu, Xiaoyan; Zhou, Xinyu et al. (2018) Chemotherapy Sensitizes Therapy-Resistant Cells to Mild Hyperthermia by Suppressing Heat Shock Protein 27 Expression in Triple-Negative Breast Cancer. Clin Cancer Res 24:4900-4912
Amer, Ahmed M; Zaid, Mohamed; Chaudhury, Baishali et al. (2018) Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer 124:1701-1709
Koay, Eugene J; Hall, William; Park, Peter C et al. (2018) The role of imaging in the clinical practice of radiation oncology for pancreatic cancer. Abdom Radiol (NY) 43:393-403
Martinez, Jonathan O; Molinaro, Roberto; Hartman, Kelly A et al. (2018) Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug delivery. Theranostics 8:1131-1145
Mai, Junhua; Li, Xin; Zhang, Guodong et al. (2018) DNA Thioaptamer with Homing Specificity to Lymphoma Bone Marrow Involvement. Mol Pharm 15:1814-1825
Krzykawska-Serda, Martyna; Agha, Mahdi S; Ho, Jason Chak-Shing et al. (2018) Chemotherapy and Radiofrequency-Induced Mild Hyperthermia Combined Treatment of Orthotopic Pancreatic Ductal Adenocarcinoma Xenografts. Transl Oncol 11:664-671
Tang, Chad; Hobbs, Brian; Amer, Ahmed et al. (2018) Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Sci Rep 8:1922
Wang, Feng; Xia, Xiaojun; Yang, Chunying et al. (2018) SMAD4 Gene Mutation Renders Pancreatic Cancer Resistance to Radiotherapy through Promotion of Autophagy. Clin Cancer Res 24:3176-3185
Kojic, M; Milosevic, M; Kojic, N et al. (2018) Mass release curves as the constitutive curves for modeling diffusive transport within biological tissue. Comput Biol Med 92:156-167

Showing the most recent 10 out of 255 publications